Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Novartis drug helps stop breast cancer’s return in large study
Novartis drug helps stop breast cancer’s return in large study
BioPharma Dive
Novartis
Kisqali
clinical trials
breast cancer
Flag link:
As Sandoz prepares to spin off from Novartis, the company sets sights on new crosstown headquarters
As Sandoz prepares to spin off from Novartis, the company sets sights on new crosstown headquarters
Fierce Pharma
Novartis
biosimilars
spinoffs
headquarters
Flag link:
Novartis buys priority review voucher from Pharming for discount price of $21M
Novartis buys priority review voucher from Pharming for discount price of $21M
Fierce Biotech
Novartis
Pharming
priority review vouchers
Flag link:
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
Fierce Pharma
ASCO 2023
Merck
Keytruda
Novartis
Kisqali
non-small cell lung cancer
early breast cancer
Flag link:
Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf
Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf
Fierce Biotech
Novartis
gene therapy
Avrobio
AVR-RD-04
Flag link:
Novartis brings on 8 business vets for Sandoz's new board, including 4 women
Novartis brings on 8 business vets for Sandoz's new board, including 4 women
Fierce Pharma
Novartis
Sandoz
biosimilars
generics
women executives
Flag link:
The waxing and waning of the speedy approval
The waxing and waning of the speedy approval
EP Vantage
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Flag link:
Sandoz taps Evotec in long-term biosimilar development and manufacturing deal
Sandoz taps Evotec in long-term biosimilar development and manufacturing deal
Fierce Pharma
Novartis
Sandoz
Evotec
biosimilars
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations
BioSpace
Biogen
Novartis
Sanofi
earnings
R&D
Flag link:
Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold
Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold
Fierce Pharma
Novartis
Sandoz
generics
Adalvo
Flag link:
'More in the hopper': European Big Pharmas hint M&A could ramp up
'More in the hopper': European Big Pharmas hint M&A could ramp up
Fierce Biotech
Europe
M&A
GSK
Novartis
Roche
Flag link:
Novartis’s iptacopan meets primary endpoint in Phase III PNH trial
Novartis’s iptacopan meets primary endpoint in Phase III PNH trial
Clinical Trials Arena
Novartis
clinical trials
PNH
iptacopan
Flag link:
Bristol Myers boosts cell therapy production with Novartis plant
Bristol Myers boosts cell therapy production with Novartis plant
BioPharma Dive
Bristol Myers Squibb
cell therapy
Novartis
drug manufacturing
Flag link:
Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas
Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas
BioSpace
Novartis
earnings
solid tumors
hematology
immunology
Neuroscience
cardiovascular disease
Flag link:
Point looks to turn the tables on Novartis
Point looks to turn the tables on Novartis
EP Vantage
Novartis
Point Biopharma
radiopharmaceuticals
Flag link:
Novartis, helped by cost cuts, raises full-year outlook
Novartis, helped by cost cuts, raises full-year outlook
Reuters
Novartis
earnings
Flag link:
Novartis strikes $425M deal with 3BP for FAP-targeting peptide technology
Novartis strikes $425M deal with 3BP for FAP-targeting peptide technology
Medical Marketing and Media
Novartis
3B Pharmaceuticals
FAP-targeting peptides
Flag link:
Novartis plant cleared to produce in-demand cancer drug
Novartis plant cleared to produce in-demand cancer drug
BioPharma Dive
Novartis
drug manufacturing
Pluvicto
New Jersey
cancer
radiopharmaceuticals
Flag link:
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Daiichi Sankyo
Astellas
Novartis
quizartinib
FDA
blood cancer
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »